Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 5/20 | 0.50 |
| ▸ | CCR3 | P51677 | 5/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6567690 | 0.82 | CCR3 (0.63) | HRH1CCR3HSD11B1HRH3KCNH2 | |
| SCHEMBL6569270 | 0.82 | HRH1 (0.58) | HRH1CCR3HSD11B1KDM4EALDH1A1 | |
| SCHEMBL6568902 | 0.81 | HRH1 (0.59) | HRH1CCR3HSD11B1KDM4EALDH1A1 | |
| SCHEMBL4719968 | 0.78 | HRH1 (0.52) | HRH1CCR3HSD11B1KDM4EALDH1A1 | |
| SCHEMBL6567607 | 0.78 | CCR3 (0.57) | HRH1CCR3HSD11B1HRH3KCNH2 | |
| SCHEMBL6570409 | 0.78 | CCR3 (0.57) | HRH1CCR3HSD11B1HRH3 | |
| Acetic Acid SCHEMBL5407035 | 0.77 | HRH1 (0.66) | HRH1CCR3HSD11B1LRRK2KCNH2 | |
| SCHEMBL5405625 | 0.75 | HRH1 (0.78) | HRH1CCR3HRH3KCNH2 | |
| SCHEMBL1912013 | 0.74 | LRRK2 (0.69) | HSD11B1KDM4EALDH1A1LRRK2 | |
| SCHEMBL6569244 | 0.74 | HRH1 (0.59) | HRH1CCR3KDM4EALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| US-20050171092-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| EP-1274701-B1 | [1,4']-BIPIPERIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-6903115-B2 | Bipiperidine compounds | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040014783-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20040006080-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 39/4885CCR3 1/4885HSD11B1 270/4885 |
| US-20050171092-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 38/4885CCR3 1/4885HSD11B1 242/4885 |
| US-20040006080-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 39/4885CCR3 1/4885HSD11B1 270/4885 |
| US-20040014783-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 39/4885CCR3 1/4885HSD11B1 270/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 38/4885CCR3 1/4885HSD11B1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.